The cutting edge research that happens within the Princess Margaret Endocrine Site Group and through its collaboration with the Ontario Cancer Institute is focused on basic, translational and population studies that aim to affect diagnosis, treatment, disease management and quality of life through innovation in technology and clinical practice across modalities.
Current studies include research on the mechanisms behind tumours of the pituitary, thyroid, adrenal glands, and pancreas, new and innovative approaches for arresting endocrine tumours, the role of adjunctive therapies, particularly in thyroid cancer, and controlled studies on the use of radioactive iodine therapy in low to moderate risk patents with thyroid cancer.
We are also active in thyroid cancer research studies focused the following areas: epidemiology, psychosocial impact of diagnosis and its treatment, survivorship concerns, summarizing medical evidence in systematic reviews of the literature, and knowledge translation.
